CN105189505B - 用作抗菌剂的三环促旋酶抑制剂 - Google Patents

用作抗菌剂的三环促旋酶抑制剂 Download PDF

Info

Publication number
CN105189505B
CN105189505B CN201380058803.6A CN201380058803A CN105189505B CN 105189505 B CN105189505 B CN 105189505B CN 201380058803 A CN201380058803 A CN 201380058803A CN 105189505 B CN105189505 B CN 105189505B
Authority
CN
China
Prior art keywords
ring
compound
group
membered
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380058803.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105189505A (zh
Inventor
丹尼尔·班森
艾伦·博哈特
陈智勇
约翰·M·芬恩
兰坦多
李淑中
李晓明
莱斯利·威廉·塔里
滕民
迈克尔·乔斯
张军虎
迈克尔·E·荣格
菲利斯·C·莱特斯通
塞尔吉奥·E·黄
端·B·阮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Lawrence Livermore National Security LLC
Original Assignee
Treus Therapeutics Co ltd
Lawrence Livermore National Security LLC
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treus Therapeutics Co ltd, Lawrence Livermore National Security LLC, Optimer Pharmaceuticals LLC filed Critical Treus Therapeutics Co ltd
Publication of CN105189505A publication Critical patent/CN105189505A/zh
Application granted granted Critical
Publication of CN105189505B publication Critical patent/CN105189505B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201380058803.6A 2012-09-12 2013-09-11 用作抗菌剂的三环促旋酶抑制剂 Active CN105189505B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700159P 2012-09-12 2012-09-12
US61/700,159 2012-09-12
PCT/US2013/059310 WO2014043272A1 (en) 2012-09-12 2013-09-11 Tricyclic gyrase inhibitors for use as antibacterial agents

Publications (2)

Publication Number Publication Date
CN105189505A CN105189505A (zh) 2015-12-23
CN105189505B true CN105189505B (zh) 2019-03-22

Family

ID=49226575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058803.6A Active CN105189505B (zh) 2012-09-12 2013-09-11 用作抗菌剂的三环促旋酶抑制剂

Country Status (7)

Country Link
US (1) US10865216B2 (enExample)
EP (1) EP2895488B1 (enExample)
JP (1) JP6460991B2 (enExample)
CN (1) CN105189505B (enExample)
AR (1) AR092538A1 (enExample)
TW (1) TWI639602B (enExample)
WO (1) WO2014043272A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
AU2012229997B2 (en) * 2011-03-15 2016-04-14 Lawrence Livermore National Security, Llc Tricyclic gyrase inhibitors
US10385055B2 (en) * 2013-09-11 2019-08-20 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
WO2016067009A1 (en) * 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
CA3024273A1 (en) 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN106588731B (zh) * 2016-12-08 2018-06-29 河北桑迪亚医药技术有限责任公司 环丙基二苯基锍三氟甲磺酸盐的合成方法
WO2018174288A1 (ja) 2017-03-24 2018-09-27 大正製薬株式会社 ２（１ｈ）－キノリノン誘導体
EP3601282B1 (en) 2017-03-30 2021-07-21 F. Hoffmann-La Roche AG Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
HRP20220790T1 (hr) 2017-05-04 2022-09-16 Bayer Cropscience Aktiengesellschaft Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
US11542248B2 (en) * 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
WO2019161494A1 (en) 2018-02-20 2019-08-29 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
JP7443351B2 (ja) * 2018-09-26 2024-03-05 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染症の治療及び予防のための、置換ピリドインドール
EP3871673B1 (en) 2018-10-26 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
CN113195503A (zh) * 2018-12-20 2021-07-30 豪夫迈·罗氏有限公司 用于治疗和预防细菌感染的氧代吡啶并[1,2-a]嘧啶化合物
WO2020225077A1 (en) * 2019-05-03 2020-11-12 Idorsia Pharmaceuticals Ltd Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
CN112574085A (zh) * 2020-12-18 2021-03-30 南通药明康德医药科技有限公司 一种5-氨基-2-氮杂螺[3.4]辛烷-2-羧酸叔丁酯的制备方法
CN112552222B (zh) * 2020-12-18 2022-08-23 南通药明康德医药科技有限公司 一种2-(2-(叔-丁氧羰基)-2-氮杂螺[3.4]辛烷-5-基)乙酸的制备方法
CN114763357B (zh) * 2021-01-15 2024-06-18 中国科学院上海药物研究所 吲哚并嘧啶三环类化合物及其制备方法和用途
CN113372352B (zh) * 2021-06-10 2022-08-26 青岛农业大学 吲哚3,4位并九元中环化合物及其制备方法
KR20250073215A (ko) * 2022-09-21 2025-05-27 브리스톨-마이어스 스큅 컴퍼니 tert-부틸 (2-아자비시클로[2.2.1]헵탄-4-일)카르바메이트 및 관련 화합물을 제조하는 방법
EP4615847A1 (en) * 2022-11-11 2025-09-17 Merck Sharp & Dohme LLC Small molecule inhibitors of kras proteins
WO2024233776A1 (en) * 2023-05-09 2024-11-14 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025240742A1 (en) * 2024-05-15 2025-11-20 Merck Sharp & Dohme Llc Protein degraders of kras g12d mutant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN157280B (enExample) * 1983-07-15 1986-02-22 Hoechst India
DE4030059A1 (de) 1990-09-22 1992-03-26 Bayer Ag Verfahren zur herstellung von 5-hydroxy-3,4,5,6-tetrahydro-pyrimidin-derivaten
DE4032560A1 (de) 1990-10-13 1992-04-16 Bayer Ag 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate
US5279359A (en) 1992-06-26 1994-01-18 Erickson Donald C Rotary trisorption heat pump
US5527910A (en) 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
AP2002002603A0 (en) 2000-01-24 2002-09-30 Warner Lambert Co 3-aminoquinazolin-2,4-dione antibacterial agents.
CA2542076C (en) * 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7776855B2 (en) 2006-07-27 2010-08-17 Janssen Pharmaceutica N.V. Antimicrobial oxazolidinone prodrugs
WO2011032050A2 (en) 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
AU2012229997B2 (en) * 2011-03-15 2016-04-14 Lawrence Livermore National Security, Llc Tricyclic gyrase inhibitors
US10385055B2 (en) * 2013-09-11 2019-08-20 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa;Pamela R. Tessier et al.;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;20130409;第57卷(第6期);2887-2889 *

Also Published As

Publication number Publication date
US20150246934A1 (en) 2015-09-03
TWI639602B (zh) 2018-11-01
WO2014043272A1 (en) 2014-03-20
JP6460991B2 (ja) 2019-01-30
AR092538A1 (es) 2015-04-22
EP2895488A1 (en) 2015-07-22
TW201425314A (zh) 2014-07-01
EP2895488B1 (en) 2024-12-11
JP2015528502A (ja) 2015-09-28
CN105189505A (zh) 2015-12-23
US10865216B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
CN105189505B (zh) 用作抗菌剂的三环促旋酶抑制剂
EP2686320B1 (en) Tricyclic gyrase inhibitors
AU2011256380B2 (en) Macrocyclic compounds as Trk kinase inhibitors
KR101692600B1 (ko) 증식성 질환 치료용 거대환형 유도체
JP2023088942A (ja) ヒト免疫不全ウイルス複製の阻害剤
WO2020156437A1 (zh) Akt抑制剂
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2023110936A1 (en) Reversible macrocyclic kinase inhibitors
CN107709312B (zh) 新型抗疟疾药物
JP7216105B2 (ja) Ｅｒｋキナーゼ阻害活性を有する化合物及びその使用
WO2025162209A1 (zh) 一种吡啶并吡啶酮类mat2a抑制剂及其药物组合物、医药用途
IL319215A (en) Preparations for administering JAK kinase inhibitors
EP4448521A1 (en) Reversible macrocyclic kinase inhibitors
CN118696041A (zh) 大环btk抑制剂
NZ614983B2 (en) Tricyclic gyrase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160302

Address after: New jersey, USA

Applicant after: Optimer Biotechnology Inc.

Applicant after: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

Address before: California, USA

Applicant before: Treus Therapeutics Co.,Ltd.

Applicant before: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221025

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Patentee after: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

Address before: new jersey

Patentee before: Optimer Biotechnology Inc.

Patentee before: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC